Social Media Listening for Melanoma Care Across European Markets

Author(s)

Chauhan J1, Aasaithambi S1, Sagkriotis A2, Lau M2, Marquez-Rodas I3, Formisano L4, Papa S5, Meyer N6, Forschner A7, Faust G8
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharma AG, Basel, Switzerland, 3Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, 4University of Naples “Federico II”, Naples, Italy, 5King's College London, London, UK, 6Toulouse Cancer Institute (IUC) and University Hospital (CHU), Toulouse, France, 7University Hospital Tübingen, Tübingen, Germany, 8University Hospitals of Leicester, Leicester, UK

Objective: The ubiquitous use of social media (SM) allows disease-specific insights to be obtained from publicly available sources. This study across 15 European countries (Austria, Belgium, France, Germany, Italy, Netherlands, Nordic countries, Portugal, Spain, Switzerland, and UK), examined the needs/perceptions of patients with melanoma using SM listening (SML).

Methods: Data was collected retrospectively over a 2-year period (Nov 2018–Sep 2020) using melanoma-specific terminology. Manual and automated relevancy approaches filtered the extracted data for content that provided patient- and country-centric insights.

Results: Out of 864 total analyzed mentions of melanoma, Twitter was the primary channel across countries, with the exception of Austria and Germany where conversations on forums were preferred. Most discussions occurred in the UK (38%), Spain (16%), Italy (13%), Germany (11%), and France (11%). With the exception of Nordic countries and Switzerland, female-led discussions were more common overall (55%).

Treatment stage was the most frequently discussed topic of the patient journey across countries, except in Austria, Germany and Belgium where diagnosis and tests were more commonly discussed (75%, 72% and 43% respectively). Surgery and immunotherapy were the most frequently discussed treatments across all territories in both first- and second-line settings.

UK and Spain were the most prominent regions for discussions on quality of life, where stakeholders mentioned emotional burden as having the biggest impact on their lives (85%; n=74, and 41%; n=37, respectively), although in Spain, social impact was more heavily discussed (Spain, 49% vs UK, 7%). Availability of effective treatments and access to good healthcare practitioners (HCPs) emerged as the most prominent unmet needs in Italy and UK, while lack of communication with HCPs was a concern in Germany.

Conclusion: SML is a valuable tool in gathering evidence from patients and other stakeholders, which can be used to establish the heterogeneity of insights from across countries.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)

Code

POSA357

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×